SLC5A1
Sodium/glucose cotransporter 1
As of the edition of 20 October 2026, SLC5A1 (sodium/glucose cotransporter 1, UniProt P13866) has 4 drugs tested at it and 4 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P13866
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 4
- Disease areas
- Nutrition and metabolism; Hormones; Pregnancy and women's health; Urinary and reproductive; Digestive system; Cancer; Heart and blood vessels; Immune system
- Registered trials of its drugs
- 22
Drugs at this target
| Status | Count |
|---|---|
| Active | 3 |
| Stopped | 1 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Licogliflozin | Stopped | Phase 2 | none listed |
| YG1699 | Active | Phase 2 | none listed |
| Mizagliflozin | Active | Phase 2 | none listed |
| SY-009 | Active | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 3 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Novartis | Route A |
The other 3 companies at SLC5A1
In the product4 companies in all; 3 are not named here, and no score is.
See the 4 companies at SLC5A1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.